Pimecrolimus

吡美莫司

Report date: 2026/03/06 20:02:51
NME

Base Information

Drug NamePimecrolimus
Drug Alias Name吡美莫斯DouglanPimecrolimusum匹美莫司Topical pimecrolimus (Novartis) +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCalcineurin inhibitorsFK506-binding protein 1A ligand
TargetsCalcineurinFK506-binding protein 1A
Therapy Area/IndicationsPrurigo NodularisPityriasisVitiligo +[12] 
Global Approved IndicationsEczemaDermatitis, Atopic
Approved Indications in ChinaEczema
Original Approved Country/TerritoryUnited States
Original Approved Date2001/12/13
Country/TerritoryBelgiumUnited StatesGermany +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma AgBausch & Lomb (Singapore) Pvi Ltd
Inactive CompaniesUtah State UniversitySt Joseph University, Beirut, LebanonActavis Inc +[11] 
Active IndicationsEczemaDermatitis, Atopic
Inactive IndicationsPrurigo NodularisPityriasisVitiligo +[10] 

Other Information

ATC CodeD11AH02
Related LinksWikipediaDrugBankKEGG